In December 2016, Shire abandoned a cancer drug targeting oxMIF it had swallowed as part of its $32 billion buyout of Baxalta earlier that year. Now former executives of the two companies have set up their own shop in Austria — banking on that same target.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,